AbCellera Biologics Inc. (ABCL)
Valuation Overview•Is AbCellera Biologics Inc. Overvalued or Undervalued?
The market is pricing the stock in line with historical averages, assuming steady-state growth.
Moderate quality score of 47/100, reflecting stable operating margins and manageable leverage.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Verdict: Average quality business weighed down by significant profitability concerns.
Wall Street is highly bullish, projecting significant upside. The company currently retains all capital for reinvestment and growth rather than returning it to shareholders.
ABCL struggles with subpar profitability and pressured margins. This is backed by a fortress balance sheet, holding significant net cash ($12M) and minimal debt risk.
The company is facing top-line contraction (-46.3% 3Y CAGR) paired with stable bottom-line earnings. However, profitability remains a major concern with severely compressed operating margins (-267.6%).
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $8.3M | +160.6% | -46.3% | -20.3% | — | |
| EBITDA | -$48.9M | — | — | — | — | |
| Net Income | -$43.2M | +10.1% | — | — | — | |
| EPS (Diluted) | $-0.14 | +10.9% | — | — | — | |
| Free Cash Flow | -$37.4M | +6.9% | — | — | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 79.1% | 87.2% | 87.2% | 90.5% |
| Operating Margin | -267.6% | -668.2% | -381.1% | -235.3% |
| Net Margin | -181.7% | -381.6% | -214.2% | -129.5% |
| FCF Margin | -238.9% | -399.8% | -221.5% | -141.9% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $-0.22 | $-0.14 | +36.4% | ||
| Q1'26 | $-0.18 | $-0.03 | +83.3% | ||
| Q4'25 | $-0.17 | $-0.19 | -11.8% | ||
| Q3'25 | $-0.17 | $-0.12 | +29.4% | ||
| Q2'25 | $-0.17 | $-0.15 | +11.8% | ||
| Q1'25 | $-0.15 | $-0.11 | +26.7% | ||
| Q4'24 | $-0.14 | $-0.17 | -21.4% | ||
| Q3'24 | $-0.15 | $-0.13 | +13.3% |
Total return is +59.4% (1Y), outperforming the benchmark by +34.4%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +61.2% | +51.9% | — |
| 1Y | +59.4% | +34.4% | — |
| 3YCAGR | -9.7% | -29.7% | — |
| 5YCAGR | -24.9% | -37.4% | — |
| 10YCAGR | -21.1% | -34.8% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about AbCellera Biologics Inc. (ABCL) valuation, health, and returns.
AbCellera Biologics Inc. is estimated to be fairly valued under our discounted cash flow framework. trading near fair value (DCF: $0.00)
AbCellera Biologics Inc. has multiple valuation anchors: DCF Intrinsic Value: $0.00 | Wall Street Analyst Target: $7.50 (implying +35.6% upside). A convergence of these signals offers higher conviction.
AbCellera Biologics Inc. displays fair financial health with a composite quality score of 47/100, supported by a Altman Z-Score of 4.7 (safe zone), Piotroski F-Score of 4/9, Return on Invested Capital (ROIC) of -15.5%.
AbCellera Biologics Inc. does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
AbCellera Biologics Inc.'s current growth trajectory is Accelerating. The company achieved +160.6% 1Y revenue growth and +10.9% 1Y EPS growth, compared to its 3Y revenue CAGR of -46.3%.
Wall Street consensus is Buy based on 11 analysts, beating EPS expectations in 75% of recent quarters with a 2-quarter streak. The consensus price target represents a +35.6% change from current levels.
Investment risks for AbCellera Biologics Inc. include: -54.9% 1-year max drawdown, high beta (2.70x market volatility). Volatility risk is characterized by a beta of 2.70x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.